Literature DB >> 31605536

Open-label pilot study of tofacitinib 2% for the treatment of refractory vitiligo.

P Mobasher1, R Guerra2, S J Li2, J Frangos2, A K Ganesan1, V Huang2,3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31605536      PMCID： PMC7124977          DOI： 10.1111/bjd.18606

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN： 0007-0963            Impact factor:   9.302


× No keyword cloud information.
  5 in total

1.  A pilot study of 2% tofacitinib cream with narrowband ultraviolet B for the treatment of facial vitiligo.

Authors:  Jacqueline McKesey; Amit G Pandya
Journal:  J Am Acad Dermatol       Date:  2019-04-19       Impact factor: 11.527

2.  Repigmentation in vitiligo using the Janus kinase inhibitor tofacitinib may require concomitant light exposure.

Authors:  Lucy Y Liu; James P Strassner; Maggi A Refat; John E Harris; Brett A King
Journal:  J Am Acad Dermatol       Date:  2017-08-18       Impact factor: 11.527

3.  Tofacitinib Citrate for the Treatment of Vitiligo: A Pathogenesis-Directed Therapy.

Authors:  Brittany G Craiglow; Brett A King
Journal:  JAMA Dermatol       Date:  2015-10       Impact factor: 10.282

4.  Treatment of vitiligo with the topical Janus kinase inhibitor ruxolitinib.

Authors:  Brooke Rothstein; Deep Joshipura; Ami Saraiya; Rana Abdat; Huda Ashkar; Yana Turkowski; Vaneeta Sheth; Victor Huang; Shiu Chung Au; Courtney Kachuk; Nicole Dumont; Alice B Gottlieb; David Rosmarin
Journal:  J Am Acad Dermatol       Date:  2017-04-05       Impact factor: 11.527

5.  A mouse model of vitiligo with focused epidermal depigmentation requires IFN-γ for autoreactive CD8⁺ T-cell accumulation in the skin.

Authors:  John E Harris; Tajie H Harris; Wolfgang Weninger; E John Wherry; Christopher A Hunter; Laurence A Turka
Journal:  J Invest Dermatol       Date:  2012-02-02       Impact factor: 8.551
  5 in total
  9 in total

Review 1.  A Literature Review Investigating the Use of Topical Janus Kinase Inhibitors for the Treatment of Vitiligo.

Authors:  Christopher White; Richard Miller
Journal:  J Clin Aesthet Dermatol       Date:  2022-04

Review 2.  [Pharmacology of Janus kinase inhibitors].

Authors:  F Solimani; F J Hilke; K Ghoreschi
Journal:  Hautarzt       Date:  2019-12       Impact factor: 0.751

Review 3.  Emerging Topical and Systemic JAK Inhibitors in Dermatology.

Authors:  Farzan Solimani; Katharina Meier; Kamran Ghoreschi
Journal:  Front Immunol       Date:  2019-12-03       Impact factor: 7.561

Review 4.  Vitiligo, From Physiopathology to Emerging Treatments: A Review.

Authors:  Laure Migayron; Katia Boniface; Julien Seneschal
Journal:  Dermatol Ther (Heidelb)       Date:  2020-09-19

Review 5.  Janus Kinase Inhibitors in the Treatment of Vitiligo: A Review.

Authors:  Fei Qi; Fang Liu; Ling Gao
Journal:  Front Immunol       Date:  2021-11-18       Impact factor: 7.561

Review 6.  Role of Cytokines in Vitiligo: Pathogenesis and Possible Targets for Old and New Treatments.

Authors:  Paolo Custurone; Luca Di Bartolomeo; Natasha Irrera; Francesco Borgia; Domenica Altavilla; Alessandra Bitto; Giovanni Pallio; Francesco Squadrito; Mario Vaccaro
Journal:  Int J Mol Sci       Date:  2021-10-22       Impact factor: 5.923

Review 7.  Current Concepts of Vitiligo Immunopathogenesis.

Authors:  Nika Hlača; Tina Žagar; Marija Kaštelan; Ines Brajac; Larisa Prpić-Massari
Journal:  Biomedicines       Date:  2022-07-08

Review 8.  Advances in vitiligo: Update on therapeutic targets.

Authors:  Yifei Feng; Yan Lu
Journal:  Front Immunol       Date:  2022-08-31       Impact factor: 8.786

Review 9.  Updates and new medical treatments for vitiligo (Review).

Authors:  David Emmanuel Kubelis-López; Natalia Aranza Zapata-Salazar; Salvador Luis Said-Fernández; Celia Nohemí Sánchez-Domínguez; Mauricio Andrés Salinas-Santander; Herminia Guadalupe Martínez-Rodríguez; Osvaldo Tomás Vázquez-Martínez; Uwe Wollina; Torello Lotti; Jorge Ocampo-Candiani
Journal:  Exp Ther Med       Date:  2021-05-25       Impact factor: 2.447
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.